XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (28,779) $ (3,190,325)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization expense 3,702,687 4,816,630
Share-based compensation 271,146 320,598
Decrease in non-cash contingent consideration (1,017,712) (1,051,908)
Decrease in cash surrender value of life insurance policies over premiums paid 16,357 708,293
Increase in noncash interest expense 11,713 7,608
Life insurance proceeds (346,800) (611,330)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 890,361 (8,184,656)
Inventories 418,355 1,338,881
Other current assets and other assets (439,320) 4,355,396
Accounts payable and other current liabilities 1,903,021 8,778,631
Other long-term liabilities (327,329) (2,472,453)
Net cash provided by operating activities 5,053,700 4,815,365
Cash flows from investing activities:    
Additions to property and equipment (232,595) (255,676)
Settlement of patent litigation 0 21,757
Life insurance policy proceeds received 0 877,597
Cash paid for acquisitions 0 (13,500,000)
Additions to intangible assets (133,739) (177,362)
Net cash used in investing activities (366,334) (13,033,684)
Cash flows from financing activities:    
Borrowings on line of credit 23,775,000 46,700,000
Repayments on line of credit (27,051,875) (44,000,000)
Cash payment of contingent consideration (2,108,933) (1,117,576)
Repurchase of common shares (551,563) (863,383)
Net cash provided by (used in) financing activities (5,937,371) 719,041
Net decrease in cash and cash equivalents (1,250,005) (7,499,278)
Cash and cash equivalents at beginning of period 19,757,970 27,040,816
Cash and cash equivalents at end of period $ 18,507,965 $ 19,541,538